Loading
A phase 1/2 trial of Alcestobart run by Nanjing Leads Biolabs Co.,Ltd, completed.
A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05102006 by Nanjing Leads Biolabs Co.,Ltd, with 80 participants enrolled, started 2021-11-30. Conditions recorded: Advanced Malignant Tumors. Interventions recorded: LBL-007 Injection and Toripalimab Injection.
Shares Alcestobart, Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/